Therefore, these results suggest that, from a phenotypic point of view, the low levels of PD‐L1 and immune markers shown in these pediatric solid tumors may not necessary support the PD‐L1 IHC biomarker approach used to develop anti‐PD‐1/PD‐L1 monotherapies in adult tumor indications. Here, CD274 is linked to neoplasm.